Who are Administration of dornase alfa's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/administration-of-dornase-alfa.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Administration of dornase alfa — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Administration of dornase alfa (Administration of dornase alfa) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DNase. Area: Respiratory.

phase 2 DNase Deoxyribonuclease I Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Administration of dornase alfa (Administration of dornase alfa) — Fondation Ophtalmologique Adolphe de Rothschild. Dornase alfa is a recombinant form of human deoxyribonuclease I that breaks down DNA in the extracellular matrix of cystic fibrosis sputum, reducing its viscosity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Administration of dornase alfa TARGET	Administration of dornase alfa	Fondation Ophtalmologique Adolphe de Rothschild	phase 2	DNase	Deoxyribonuclease I

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DNase class)

Fondation Ophtalmologique Adolphe de Rothschild · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Administration of dornase alfa — Competitive Intelligence Brief. https://druglandscape.com/ci/administration-of-dornase-alfa. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab